Gadovist 1.0 mmol/ml solution for injection in prefilled syringe

Main information

  • Trade name:
  • Gadovist 1.0 mmol/ml solution for injection in prefilled syringe
  • Dosage:
  • 1.0 millimole(s)/millilitre
  • Pharmaceutical form:
  • Solution for injection
  • Prescription type:
  • Product subject to Restricted Prescription (C)
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Gadovist 1.0 mmol/ml solution for injection in prefilled syringe
    Ireland
  • Language:
  • English

Therapeutic information

  • Therapeutic area:
  • Paramagnetic contrast media; gadobutrol

Status

  • Source:
  • HPRA - Health Products Regulatory Authority - Ireland
  • Authorization status:
  • Not marketed
  • Authorization number:
  • PA1410/018/002
  • Authorization date:
  • 20-04-2001
  • Last update:
  • 21-03-2019

Patient Information leaflet: composition, indications, side effects, dosage, interactions, adverse reactions, pregnancy, lactation

17194

Package leaflet: Information for the patient

Gadovist 1.0 mmol/ml solution for injection in prefilled syringe

Gadobutrol

Read all of this leaflet carefully before you are given this medicine because it contains important

information for you.

Keep this leaflet. You may need to read it again.

If you have any further questions, please ask your doctor or the person giving you Gadovist (the

radiologist) or the hospital/MRI-centre personnel.

If you get any side effects talk to your doctor or radiologist. This includes any possible side effects not

listed in this leaflet. See section 4.

What is in this leaflet

What Gadovist is and what it is used for

What you need to know before you are given Gadovist

How Gadovist will be given

Possible side effects

How to store Gadovist

Contents of the pack and other information

1.

What Gadovist is and what it is used for

Gadovist is a contrast medium for magnetic resonance imaging (MRI) used for diagnostics of the brain, spine

and vessels. Gadovist can also help the doctor find out the kind (benign or malignant) of known or suspected

abnormalities in the liver and kidneys.

Gadovist can also be used for MRI of abnormalities of other body regions.

It facilitates visualisation of abnormal structures or lesions and helps in the differentiation between healthy

and diseased tissue.

It is for use in adults and children of all ages (including term newborn infants).

How Gadovist works

MRI is a form of medical diagnostic imaging that uses the behaviour of water molecules in normal and

abnormal tissues. This is done by a complex system of magnets and radio waves. Computers record the

activity and translate that into images.

Gadovist is given as an injection into your vein. This medicine is for diagnostic use only and will only be

administered by healthcare professionals experienced in the field of clinical MRI practice.

2.

What you need to know before you are given Gadovist

Do NOT use Gadovist if you

are allergic to gadobutrol or any of the other ingredients of this medicine (listed in section 6).

17194

Warnings and precautions

Talk to your doctor before you are given Gadovist if you

suffer or have suffered from an allergy (e.g. hay fever, hives) or asthma

had a previous reaction to any contrast media

have very poor kidney function

suffer from brain conditions with seizures (fits) or from other diseases of the nervous system

have a heart pacemaker or if there are any implants or clips containing iron in your body.

Your doctor will decide whether the intended examination is possible or not.

Allergy-like reactions leading to heart problems, breathing difficulties or skin reactions may occur

after use of Gadovist. Severe reactions are possible. Most of these reactions occur within half an hour

after you are given Gadovist. Therefore, you will be observed after the examination. Delayed reactions

have been observed (after hours or days) (see section 4).

Kidneys/Liver

Tell your doctor if

your kidneys do not work properly

you have recently had, or soon expect to have, a liver transplant.

Your doctor may decide to take a blood test to check how well your kidneys are working before making the

decision to use Gadovist, especially if you are 65 years of age or older.

Neonates and infants

As kidney function is immature in babies up to 4 weeks of age and infants up to 1 year of age, Gadovist will

only be used in these patients after careful consideration by the doctor.

Other medicines and Gadovist

Tell your doctor if you are taking or have recently taken or might take any other medicines.

Pregnancy and breast-feeding

Ask your doctor for advice before taking any medicine.

Pregnancy

You must tell your doctor if you think you are, or might become, pregnant as Gadovist should not be used

during pregnancy unless strictly necessary.

Breast-feeding

Tell your doctor if you are breast-feeding or about to start breast-feeding. Your doctor will discuss whether

you should continue or interrupt breast-feeding for a period of 24 hours after you receive Gadovist.

Gadovist contains sodium

This medicinal product contains less than 23 mg sodium per dose (based on the average amount given to a

70 kg person), i.e. essentially ‘sodium-free’.

3.

How Gadovist will be given

Gadovist is injected into your vein using a small needle by a healthcare professional. Your MRI examination

can start immediately.

After the injection you will be observed for at least 30 minutes.

17194

The usual dose

The actual dose that is right for you will depend on your body weight and on the region being examined by

MRI:

In adults a single injection of 0.1 millilitre Gadovist per kg body weight is generally sufficient (this means

for a person weighing 70 kg the dose would be 7 millilitre), however a further injection of up to 0.2 millilitre

per kg body weight within 30 minutes of the first injection may be given. A total amount of 0.3 millilitre

Gadovist per kg body weight may be given.

Further information regarding the administration and handling of Gadovist is given at the end of the leaflet.

Dosage in special patient groups

The use of Gadovist is not recommended in patients with severe kidney problems and patients who have

recently had, or soon expect to have, a liver transplant. However if use is required you should only receive

one dose of Gadovist during a scan and you should not receive a second injection for at least 7 days.

Neonates, infants, children and adolescents

In children of all ages (including term newborn infants) a single dose of 0.1 millilitre Gadovist per kg body

weight is recommended for all examinations (see section 1).

As kidney function is immature in babies up to 4 weeks of age and infants up to 1 year of age, Gadovist will

only be used in these patients after careful consideration by the doctor. Neonates and infants should only

receive one dose of Gadovist during a scan and should not receive a second injection for at least 7 days.

Elderly

It is not necessary to adjust your dose if you are 65 years of age or older but you may have a blood test to

check how well your kidneys are working.

If you receive more Gadovist than you should

Overdosing is unlikely. If it does happen, the doctor will treat any symptoms and may use kidney dialysis to

remove Gadovist from your body.

There is no evidence to suggest that this will prevent the development of Nephrogenic Systemic Fibrosis

(NSF; see section 4) and it should not be used as treatment for the condition. In some cases your heart will be

checked.

If you have any further questions on the use of this medicine, ask your doctor or radiologist.

4.

Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

The most serious side effects (which have been fatal or life-threatening in some cases) are:

heart stops beating (cardiac arrest) and severe allergy-like (anaphylactoid) reactions (including stop

of breathing and shock).

In addition for the following side effects life-threatening or fatal outcomes have been observed in some

cases:

shortness of breath (dyspnoea), loss of consciousness, severe allergy-like reaction, severe decrease of

blood pressure may lead to collapse, stop of breathing, fluid in the lungs, swelling of mouth and throat

and low blood pressure.

17194

In rare cases:

allergy-like reactions (hypersensitivity and anaphylaxis) may occur, including severe reactions

(shock) that may need immediate medical intervention.

If you notice:

swelling of the face, lips, tongue or throat

coughing and sneezing

difficulty breathing

itching

runny nose

hives (nettle-type rash)

tell the MRI department staff immediately. These may be the first signs that a severe reaction is

happening. Your investigation may need to be stopped and you may need further treatment.

Delayed allergy-like reactions, hours to several days after you have received Gadovist, have been observed

in rare cases. If this should happen to you, tell your doctor or radiologist immediately.

The most frequently observed side effects (may affect 5 or more in 1,000 people) are:

headache, feeling sick (nausea) and dizziness.

Most of the side effects are mild to moderate.

Possible side effects which have been observed in clinical trials before the approval of Gadovist are listed

below by how likely they are.

Common (may affect up to 1 in 10 people)

headache

feeling sick (nausea)

Uncommon (may affect up to 1 in 100 people)

allergy-like reaction, e.g.

low blood pressure

hives

swelling of the face

swelling (oedema) of the eyelid

flushing

The frequency of the following allergy-like reactions is not known:

severe allergy-like reaction (anaphylactoid shock)

severe decrease of blood pressure may lead to collapse (shock)

breathing stops

fluid in the lungs

breathing difficulties (bronchospasm)

blueness of the lips

swelling of the mouth and throat

swelling of the throat

increased blood pressure

chest pain

swelling of the face, throat, mouth, lips and/or tongue (angioedema)

conjunctivitis

increased sweating

cough

sneezing

17194

burning sensation

pale skin (pallor)

dizziness, disturbed sense of taste, numbness and tingling

shortness of breath (dyspnoea)

vomiting

redness of the skin (erythema)

itching (pruritus including generalized pruritus)

rash (including generalized rash, small flat red spots [macular rash], small, raised, circumscribed

lesions [papular rash] and itchy rash [pruritic rash])

various kinds of injection site reactions (e.g. leakage into the surrounding tissue, burning, coldness,

warmth, reddening, rash, pain or bruising)

feeling hot

Rare (may affect up to 1 in 1,000 people)

fainting

convulsion

disturbed sense of smell

rapid heart beat

palpitations

dry mouth

generally feeling unwell (malaise)

feeling cold

Additional side effects which have been reported after the approval of Gadovist with unknown

frequency (frequency cannot be estimated from the available data):

Heart stops beating (cardiac arrest)

There have been reports of nephrogenic systemic fibrosis - NSF (which causes hardening of the skin

and may affect also soft tissue and internal organs).

Variations in blood tests of the kidney function (e.g. increase of serum creatinine) have been observed after

administration of Gadovist.

Reporting of side effects

If you get any side effects talk to your doctor or radiologist. This includes any possible side effects not listed

in this leaflet. You can also report side effects directly via HPRA Pharmacovigilance, Earlsfort Terrace, IRL

– Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: medsafety@hpra.ie.

By reporting side effects you can help provide more information on the safety of this medicine.

5.

How to store Gadovist

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label and the carton after EXP. The

expiry date refers to the last day of that month. This medicinal product does not require any special storage

conditions.

Chemical, physical and microbiological in-use stability has been demonstrated for 24 hours at 20-25°C.

From a microbiological point of view, the product should be used immediately after opening.

17194

This medicinal product is a clear, colorless to pale yellow solution. Do not use this medicine if you notice

severe discoloration or the presence of particulate matter or if the container appears defective.

Medicines should not be disposed of via wastewater or household waste. The healthcare professional will

dispose of this medicine when no longer required. These measures will help to protect the environment.

6.

Contents of the pack and other information

What Gadovist contains

The active substance is gadobutrol.

1 ml of solution for injection contains 604.72 mg gadobutrol (equivalent to 1.0 mmol gadobutrol containing

157.25 mg gadolinium).

1 prefilled syringe with 5.0 ml contains 3023.6 mg gadobutrol,

1 prefilled syringe with 7.5 ml contains 4535.4 mg gadobutrol,

1 prefilled syringe with 10 ml contains 6047.2 mg gadobutrol,

1 prefilled syringe with 15 ml contains 9070.8 mg gadobutrol,

1 prefilled syringe with 20 ml contains 12094.4 mg gadobutrol.

The other ingredients are calcobutrol sodium (see end of section 2), trometamol, hydrochloric acid 1N and

water for injections.

What Gadovist looks like and contents of the pack

Gadovist is a clear, colourless to pale yellow solution for injection.

The contents of the packs are:

1 or 5 prefilled syringes with 5, 7.5, 10 ml solution for injection (in 10-ml glass prefilled syringe)

1 or 5 prefilled syringes with 15 ml solution for injection (in 17-ml glass prefilled syringes)

1 or 5 prefilled syringes with 20 ml solution for injection (in 20-ml glass prefilled syringe)

Hospital pack:

5 prefilled syringes with 5, 7.5, 10, 15, 20 ml solution for injection

Not all pack sizes may be marketed.

Marketing Authorisation Holder

Bayer Limited

The Atrium

Blackthorn Road

Dublin 18

Manufacturer

Bayer AG

Müllerstrasse 178

13353 Berlin

Germany

17194

This medicinal product is authorised in the Member States of the EEA under the following names:

Austria, Germany

Gadovist 1,0 mmol/ml Injektionslösung in

Fertigspritzen/Patronen

Belgium, Denmark, Finland, Greece, Italy,

Luxembourg, Norway, Portugal, Sweden

Gadovist

Croatia

Gadovist 1,0 mmol/ml otopina za injekciju u

napunjenoj štrcaljki/ulošku

France

GADOVIST 1,0 mmol/mL, solution injectable

en seringue préremplie

Ireland

Gadovist 1.0 mmol/ml solution for injection in

prefilled syringe

Netherlands

Gadovist 1,0 mmol/ml, oplossing voor injectie

in voorgevulde spuit/ patroon

Spain

Gadovist 1 mmol/ml solución inyectable en

jeringa precargada / cartucho precargado

United Kingdom

Gadovist 1.0 mmol/ml solution for injection pre-

filled syringe / cartridge

This leaflet was last revised in November 2017

-----------------------------------------------------------------------------------------------------------------------------

The following information is intended for healthcare professionals only:

Renal impairment

Prior to administration of Gadovist, it is recommended that all patients are screened for renal

dysfunction by obtaining laboratory tests.

There have been reports of nephrogenic systemic fibrosis (NSF) associated with use of some gadolinium-

containing contrast agents in patients with acute or chronic severe renal impairment

(GFR < 30 ml/min/1.73 m

). Patients undergoing liver transplantation are at particular risk since the

incidence of acute renal failure is high in this group. As there is a possibility that NSF may occur with

Gadovist, it should therefore only be used in patients with severe renal impairment and in patients in the

perioperative liver transplantation period after careful risk/benefit assessment and if the diagnostic

information is essential and not available with non-contrast enhanced MRI. If it is necessary to use Gadovist,

the dose should not exceed 0.1 mmol/kg body weight. More than one dose should not be used during a scan.

Because of the lack of information on repeated administration, Gadovist injections should not be repeated

unless the interval between injections is at least 7 days.

As the renal clearance of Gadovist may be impaired in the elderly, it is particularly important to screen

patients aged 65 years and older for renal dysfunction.

Haemodialysis shortly after Gadovist administration may be useful at removing Gadovist from the body.

There is no evidence to support the initiation of haemodialysis for prevention or treatment of NSF in patients

not already undergoing haemodialysis.

17194

Pregnancy and breast-feeding

Gadovist should not be used during pregnancy unless the clinical condition of the woman requires use of

Gadovist.

Continuing or discontinuing of breast-feeding for a period of 24 hours after administration of Gadovist,

should be at the discretion of the doctor and lactating mother.

Hypersensitivity reactions

As with other intravenous contrast agents, Gadovist can be associated with anaphylactoid/hypersensitivity or

other idiosyncratic reactions, characterized by cardiovascular, respiratory or cutaneous manifestations, and

ranging to severe reactions including shock. In general, patients with cardiovascular disease are more

susceptible to serious or even fatal outcomes of severe hypersensitivity reactions.

The risk of hypersensitivity reactions may be higher in case of:

previous reaction to contrast media

history of bronchial asthma

history of allergic disorders

In patients with an allergic disposition the decision to use Gadovist must be made after particularly careful

evaluation of the risk-benefit ratio.

Most of these reactions occur within half an hour of administration. Therefore, post-procedure observation

of the patient is recommended.

Medication for the treatment of hypersensitivity reactions as well as preparedness for institution of

emergency measures are necessary.

Delayed reactions (after hours up to several days) have been rarely observed.

Seizure disorders

Like with other gadolinium containing contrast agents special precaution is necessary in patients with a low

threshold for seizures.

Overdose

In case of inadvertent overdosage, cardiovascular monitoring (including ECG) and control of renal function

are recommended as a measure of precaution.

In case of overdose in patients with renal insufficiency, Gadovist can be removed by haemodialysis. After

3 haemodialysis sessions approx. 98 % of the agent are removed from the body. However, there is no

evidence that haemodialysis is suitable for prevention of nephrogenic systemic fibrosis (NSF).

Before injection

This product is intended for single use only.

This medicinal product is a clear, colourless to pale yellow solution. It should be visually inspected before

use.

Gadovist should not be used in case of severe discoloration, the occurrence of particulate matter or a

defective container.

17194

Instructions for use

Prefilled syringes

The prefilled syringe must be taken from the pack and prepared for the injection immediately before the

administration.

The tip cap should be removed from the prefilled syringe immediately before use.

Glass syringe:

HAND INJECTION

1. Open the package

2. Screw the plunger on the syringe

3. Break the protective cover

4. Remove the protective cover

5. Remove the rubber stopper

6. Remove the air in the syringe

Any solution not used in one examination is to be discarded in accordance with local requirements.

Shelf life after first opening of the container

Any solution for injection not used in one examination must be discarded. Chemical, physical and

microbiological in-use stability has been demonstrated for 24 hours at 20-25°C. From a microbiological

point of view, the product should be used immediately. If not used immediately, in-use storage times and

conditions prior to use are the responsibility of the user.

The peel-off tracking label on the syringes should be stuck onto the patient record to enable accurate

recording of the gadolinium contrast agent used. The dose used should also be recorded. If electronic patient

records are used, the name of the product, the batch number and the dose should be entered into the patient

record.

17194

Posology

The lowest dose that provides sufficient enhancement for diagnostic purposes should be used. The dose

should be calculated based on the patient’s body weight, and should not exceed the recommended dose per

kilogram of body weight detailed in this section.

Adults

CNS indications

The recommended dose for adults is 0.1 mmol per kilogram body weight (mmol/kg BW). This is equivalent

to 0.1 ml/kg BW of the 1.0 M solution.

If a strong clinical suspicion of a lesion persists despite an unremarkable MRI or when more accurate

information might influence therapy of the patient, a further injection of up to 0.2 ml/kg BW within

30 minutes of the first injection may be performed.

Whole Body MRI (except MRA)

In general, the administration of 0.1 ml Gadovist per kg body weight is sufficient to answer the clinical

question.

CE-MRA

Imaging of 1 field of view (FOV): 7.5 ml for body weight below 75 kg; 10 ml for body weight of 75 kg and

higher (corresponding to 0.1-0.15 mmol/kg BW).

Imaging of > 1 field of view (FOV): 15 ml for body weight below 75 kg; 20 ml for body weight of 75 kg and

higher (corresponding to 0.2-0.3 mmol/kg BW).

Paediatric population

For children of all ages (including term neonates) the recommended dose is 0.1 mmol gadobutrol per kg

body weight (equivalent to 0.1 ml Gadovist per kg body weight) for all indications (see section 1).

Due to immature renal function in neonates up to 4 weeks of age and infants up to 1 year of age, Gadovist

should only be used in these patients after careful consideration at a dose not exceeding 0.1 mmol/kg body

weight. More than one dose should not be used during a scan. Because of the lack of information on repeated

administration, Gadovist injections should not be repeated unless the interval between injections is at least

7 days.

Imaging

The dose required is administered intravenously as a bolus injection. Contrast-enhanced MRI can commence

immediately afterwards (shortly after the injection depending on the pulse sequences used and the protocol

for the examination).

Optimal signal enhancement is observed during arterial first pass for CE-MRA and within a period of about

15 minutes after injection of Gadovist for CNS indications (time depending on type of lesion/tissue).

T1 -weighted scanning sequences are particularly suitable for contrast-enhanced examinations.

Further information regarding the use of Gadovist is given in section 3 of the leaflet.